A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

NCT05079633 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL: Homologous boost schedule
BIOLOGICAL: Heterologous boost schedule

Sponsor

National Taiwan University Hospital